Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Prostate cancer treatment often involves androgen deprivation therapy.
• Prostate-specific antigen (PSA) is a key biomarker in prostate cancer management.
• Understanding drug effects on PSA independent of cell growth is crucial.

Purpose of the Study:

• To evaluate the in vitro antiproliferative effects of goserelin, bicalutamide, and cyproterone acetate.
• To determine if these agents affect PSA mRNA and protein expression independently of growth inhibition.

Main Methods:

• Utilized LNCaP and C4-2 prostate cancer cell lines.
• Assessed cell proliferation using the MTT assay.
• Quantified PSA mRNA via real-time PCR and PSA protein secretion via enzyme-immunoassay.

Main Results:

• Goserelin inhibited cell growth and PSA protein secretion; PSA mRNA remained unchanged.
• Bicalutamide decreased PSA protein secretion but did not affect cell growth or PSA mRNA.
• Cyproterone acetate reduced C4-2 cell growth but had no impact on PSA mRNA or protein.

Conclusions:

• Prostate-specific antigen (PSA) expression does not always correlate with cell growth inhibition.
• Bicalutamide reduces PSA synthesis without significant growth inhibition, while cyproterone acetate inhibits growth without affecting PSA secretion.
• PSA is not a definitive surrogate marker for prostate cancer cell growth in clinical trials.